Company Highlights
Patients with EOE
472K1
estimated adults in the
US with EoE in 2022
Growth Rate
10 %
annual growth in the
number of patients
diagnosed with EoE in
the US
Unmet Need
1Only
product currently
approved for long term
use in the US
Total Addressable Market
48 $B*
*Based on 2022 prevalence
and wholesale acquisition
cost of Dupixent as per EoE label
1.Prevalence and Costs of Eosinophilic Esophagitis in the United States Thel, Hannah L. et al. Clinical Gastroenterology and Hepatology, Volume 23, Issue 2, 272 - 280.e8
Corporate Presentation
